This page is available in multiple languages
Select Language

Acticor Biotech lists on Euronext Growth Paris


  • €15.5 million raised
  • Market capitalisation of €75 million
  • French Tech 120 company
  • 5th listing of a biotech company on Euronext Paris in 2021

Paris – 02 November 2021 – Euronext today congratulates Acticor Biotech, a biopharmaceutical company specialised in the treatment of thrombotic diseases, on its listing on Euronext Growth Paris (ticker code: ALACT).

Acticor Biotech is a clinical-stage biotechnology company specialising in the development of drugs for the treatment of cardiovascular emergencies. In particular, Acticor Biotech is developing a first-in-class drug for the treatment of strokes, glenzocimab, for which two phase-2 clinical trials have already been completed. The Initial Public Offering (IPO) of Acticor Biotech aims to raise the necessary resources for its research and development operations in order to commercialise its final product, glenzocimab, as well as to extend its clinical development to other pathologies such as the pulmonary embolism and the myocardial infarction.

Acticor Biotech was listed through the admission to trading on 1 November 2021 of the 10,545,776 shares making up its equity and of 2,178,176 new shares issued under a Global Offering[1].

The admission and issue price of Acticor Biotech shares was set at €7.12 per share. Market capitalisation was €75 million on the day of listing. The offering raised €15.5 million altogether.

Gilles Avenard, co-founder and Managing Director of Acticor Biotech, says: “We are very happy to be going forward today with the listing of Acticor Biotech on Euronext. This IPO is a key step in the development of Acticor Biotech and of its first-in-class drug, glenzocimab. This drug, which is currently in two phase 2 clinical trials, has already demonstrated its good safety profile in combination with reference treatments. Significant medical progress will be possible in 2022 for the treatment of strokes, pulmonary embolism and even acute respiratory distress syndromes linked to COVID-19.”

Acticor Biotech

Caption: Gilles Avenard, co-founder and Managing Director of Acticor Biotech, and his team rang the bell during a virtual ceremony this morning, in presence of Jérôme Hervé, Listing Director SME Ile-de-France and Nouvelle-Aquitaine at Euronext, to celebrate the IPO of the company.

About Acticor Biotech Acticor Biotech is a clinical stage biotechnology company, a spin-off of INSERM (the French National Institute of Health and Medical Research), dedicated to developing an innovative treatment for cardiovascular emergencies, including ischemic stroke. Acticor Biotech has been built on the expertise and research undertaken by its co-founders: Dr. Martine Jandrot-Perrus at INSERM Paris,Prof. Philippe Billiald at Paris-Sud University and Dr Gilles Avenard. Acticor Biotech is a partner in the BOOSTER consortium, dedicated to the management of, and novel treatments for, cerebrovascular accidents in emergency situations. Acticor Biotech is supported by a panel of European and International investors: Karista, Go Capital, Newton Biocapital, CMS Ventures, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and Armesa Foundation. For more information, go to:

[1] The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.